An unusual rise in funding costs tied to hundreds of billions of dollars’ worth of equity investments is squeezing some of ...

This is mainly due to high capital costs. “It’s still an expensive proposition to install some of these systems,” he told The Northern Miner’s western editor, Henry Lazenby. McCracken ...

Pharmaceutical companies are characterized by high capital expenditures ... for pharmaceutical companies are those related to R&D costs and the company's ability to manage high levels of debt ...

The report prepared by global energy think tank Ember said project-commissioning delays and uncertainties related to new age 'Firm and Dispatchable Renewable Energy' (FDRE) projects could raise ...